A.A. Brandes

Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group

Roger Stupp, Warren Mason, Martin J. van den Bent et al. · Journal of Clinical Oncology · 2004 · 90 citations

Medicine, Oncology, Radiation Oncology +17

Randomized phase II trial of erlotinib (E) versus temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC 26034

Martin J. van den Bent, A.A. Brandes, R. Rampling et al. · Journal of Clinical Oncology · 2007 · 53 citations

Medicine, Oncology, Pharmacology +17

Expression-based intrinsic glioma subtypes are prognostic in low-grade gliomas of the EORTC22033-26033 clinical trial

Ya Gao, Bas Weenink, Martin J. van den Bent et al. · European Journal of Cancer · 2018 · 39 citations

Medicine, Cancer Biology, Oncology +15

A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme

James Perry, Chris J. O’Callaghan, Keyue Ding et al. · Neuro-Oncology · 2010 · 26 citations

Medicine, Geriatric Medicine, Oncology +17

First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma

Martin J. van den Bent, J. Delattre, A.A. Brandes et al. · Journal of Clinical Oncology · 2005 · 22 citations

Medicine, Oncology, Radiation Oncology +16